Harnessing the power of the immune system to improve lives and eradicate cancer

Nasdaq: BOLT

August 2026

BOLT BIOTHERAPEUTICS

Disclaimer

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding Bolt Biotherapeutics, Inc. (the "Company," "we," "us," or "our")'s future financial condition, ability to achieve upcoming milestones for our product candidates, the timing of our clinical trials, and the success and results of our pipeline programs and partnerships, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potentially" "predict," "should," "will" or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: the advancement and success of our clinical trial for BDC-4182, the viability of the Boltbody™ ISAC platform, the anti-tumor potency, safety and tolerability, and characteristics of our product candidates, the success, cost and timing of our product development activities and clinical trials; our expectations about the timing of achieving regulatory approval and the cost of our development programs; our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates; our ability to fund our clinical programs and the sufficiency of our cash, cash equivalents, and marketable securities to fund operations through key milestones and the achievement of key milestones; the commercialization of our product candidates, if approved; our plans to research, develop, and commercialize our product candidates; our ability to attract collaborators with development, regulatory and commercialization expertise; future agreements with third parties in connection with the commercialization of our product candidates; the success of our current collaborations with third parties, including our collaborations with Genmab A/S and Toray Industries, Inc.; the achievement of milestone payments or any tiered royalties related to our collaborations; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; the rate and degree of market acceptance of our product candidates; and regulatory developments in the United States and foreign countries. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to our Annual Report on Form 10-K for the year ended December 31, 2025. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward- looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation.

In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this presentation, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

BOLT BIOTHERAPEUTICS

BOLT is Pioneering a New Approach to Cancer Treatment

BDC-4182 will provide proof-of-concept for the ISAC approach

BDC-4182 (claudin 18.2 ISAC) Phase 1/2 clinical trial ongoing

- First-in-class, best-in-class Immune Stimulating Antibody Conjugate (ISAC)
- Initial clinical data from >10 patients will be presented with 3Q26 results



ISAC proof-of-concept should have a substantial multiplier effect

- ISACs have potential to combine the power of ADCs with the durability of T cell engagers
- Industry is hungry for ADC payloads beyond Topo1 to overcome resistance issues
- Pipeline of Boltbody™ ISACs (CEA, PD-L1, Genmab & Toray collaboration programs)

Operating runway into 1Q27[1]

- BDC-4182 initial clinical data expected to be a key inflection point

[1] Cash, cash equivalents, and marketable securities balance of $18.1 million as of 6/30/2026

BOLT BIOTHERAPEUTICS

Boltbody ISACs Could Be the Next Wave After ADCs

US ADC Sales Are >$14B, Payload Resistance Restricts Retreatment



Product	Target	Launch	Payload
Mylotarg	CD33	2000	ENED
Adcetris	CD30	2011	MTI
Kadcyla	HER2	2013	MTI
Besponsa	CD22	2017	ENED
Polivy	CD79b	2019	MTI
Padcev	Nectin-4	2019	MTI
Enhertu	HER2	2019	Topo1
Trodelvy	Trop-2	2020	Topo1
Blenrep	BCMA	2020	MTI
Zynlonta	CD19	2021	PBD
Tivdak	Tissue	2021	MTI
Elahere	FRα	2022	MTI
Datroway	Trop-2	2025	Topo1
Emrelis	c-Met	2025	MTI

ADCs Have Driven >$100 Billion in M&A

Company	Payload	Upfront ($B)	Year
Seagen	MTI	43.0	2023
Immunomedics	Topo1	21.0	2020
ImmunoGen	MTI	10.1	2023
RayzeBio	Radio	4.1	2023
Advanced Accelerator	Radio	3.9	2017
Tubulis	Topo1	3.2	2026
Algeta	Radio	2.9	2013
VelosBio	MTI	2.8	2020
Endocyte	Radio	2.1	2018
Fusion Pharmaceuticals	Radio	2.0	2024
Ambrx Biopharma	MTI	2.0	2024
ProfoundBio	Topo1	1.8	2024
POINT Biopharma	Radio	1.4	2023
Mariana Oncology	Radio	1.0	2024

Boltbody™ immunostimulatory payloads are unique and potentially superior

ENED = DNA cleaver; MTI = microtubule inhibitor; Topo1 = topoisomerase 1 inhibitor; PBD = DNA crosslinker

Pioneering a New Class of Immuno-oncology Products:
Immune-stimulating Antibody Conjugates (ISACs)

Boltbody™ ISAC



Tumor-targeting Antibody

- Geo-locates ISAC to antigen on surface of a tumor cell
- Active Fc region drives antibody-dependent cellular phagocytosis (ADCP)

Immune-stimulating Linker-payload

- Potent stimulator of the innate immune system
- Non-cleavable linker
- Cell membrane impermeable

Ackerman SE, et al. Nature Cancer. 2021;2:18–33.

BOLT BIOTHERAPEUTICS

Boltbody™ ISAC Mechanism of Action

Broad activation of the immune system to enable durable responses and bystander killing of antigen-negative tumors



Boltbody™ ISAC Approach Improves on ADCs and TCEs

	Durability	Bystander	Immune Activation	Killing Mechanism	Resistance
Boltbody™ ISACs	High	High	High	T cells + Phagocytes	-
Naked mAbs	Low/Med	-	Low	ADCC & CDC	Low antigen expression
T cell Engagers	Med	Low/Med	Med	T cells	Exhaustion & Exclusion
ADCs	Low	Med	Low/Med	Chemotherapy	Efflux & Payload Resistance

Lower — Higher

Bolt's ISACs broadly activate the immune system to enable durable responses and killing of antigen-negative tumors

BDC-4182: Claudin 18.2 Boltbody™ ISAC Program

Phase 1/2 clinical trial ongoing, initial results expected with 3Q26 financial results

BDC-4182



Next-Generation Claudin 18.2 ISAC

BDC-4182 Opportunity

- Phase 1/2 clinical trial ongoing for best-in-class claudin 18.2 ISAC
- Claudin 18.2 is a clinically validated target in gastric cancer
- This is a large market with significant unmet need

Key Attributes

- ISAC mechanism combines power of ADCs with durability of TCEs
- Immunological memory should improve durability
- Activity in low-antigen-density tumors could expand the market

Preclinical Differentiation in Competitive Claudin 18.2 Landscape

- Superior efficacy versus TOPO1 and MMAE-ADCs in multiple experiments
- Epitope spreading to also kill tumors that no longer express claudin 18.2
- Potential for better tolerability than other claudin-18.2-targeting agents

Preclinical data published in Fu CL et al. SITC 2025 and Fu CL et al. SITC 2024

BOLT BIOTHERAPEUTICS

BDC-4182 Phase 1/2 Clinical Trial in 2L+ Gastric or Gastroesophageal Cancer

Dose Escalation with Cycle 1 Step-Up Dosing



Target Doses Administered Q2W

- Open for enrollment in Australia, South Korea, and Taiwan (NCT06921837)
- CLDN18.2 IHC 2+ ≥ 1%
- **Currently treating patients at therapeutically relevant doses based on preclinical modeling**

BOLT BIOTHERAPEUTICS

Gastric Cancer Opportunity

Gastric Cancer is Common and Difficult to Treat

Gastric cancer is the 5th most common malignancy worldwide, with one million new cases annually[1]

- More than 30,000 new cases and 10,000 deaths per year In the US [1,2]

More than 50% of patients have advanced, incurable disease upon diagnosis[3,4]

- Gastric adenocarcinomas typically develop slowly with early changes rarely causing symptoms
- Only 3 of 10 patients have localized disease at diagnosis





[1] World Cancer Research Fund – Stomach Cancer Statistics, accessed Aug 2025: 970K cases in 2022
[2] SEER - Cancer Stat Facts: Stomach Cancer, accessed Aug 2025. 2025: 30,300 new cases, 10,780 deaths
[3] Cancer.org – Gastric Cancer, accessed Aug 2025
[4] Mansfield PF, et al., Clinical features, diagnosis, and staging of gastric cancer

BOLT BIOTHERAPEUTICS

Patients with Metastatic/Unresectable Gastric Cancer have Few Options

Average progression-free survival in 2L setting is 2-7 months



Source: NCCN Guidelines Gastric Cancer, Version 2. 2025. Abbreviations: FOLFOX – Fluorouracil (generally with Leucovarin) + oxaliplatin; CAPOX – capecitabine + oxaliplatin. MSI-H – Microsatellite instability-high; dMMR – DNA mismatch repair; TMB – Tumour mutational burden. Note: zolbetuximab efficacy based on final pooled analysis; 2L efficacy based on ramucirumab monotherapy and combination data

BOLT BIOTHERAPEUTICS

Claudin 18.2: Validated Target with Opportunity to Improve on Zolbetuximab

BDC-4182 has potential to improve depth and duration of response in large market

CLDN18.2 Highly Expressed in Gastric Cancer

Tumor Type	Prevalence
Gastric	>50%
Esophageal	>50%
Pancreatic	>50%
Ovarian	>10%
NSCLC	>4%

Zolbetuximab Validates the Target

Endpoint	Zolbe + Chemo	Chemo (alone)
OS (mo)	14.4 - 18.2	12.2 - 15.5
PFS (mo)	8.2 - 10.6	6.8 - 8.7
ORR	32 - 40%	31 - 40%

Clear Survival Improvements in CLDN-18.2-high patients

Large Near-term Market Opportunity

Gastric Cancer TAM: ~$7.8 Billion

- US, EU, Japan, China
- 1L-3L Opportunity
- Expansion into pancreatic/ other tumor types

Expression data: Shitara et. al. ASCO, Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2024), AstraZeneca Epidemiology Data 2022
Clinical data: Tureci, Annals of Oncology 2019 – 4 PRs noted in 43 patients with >50% CLDN18.2 expression cut-off, all of which had > 70% which subgroup was 29 patients. Zolbe alone was 9-14% ORR
TAM: Adapted from Globe Life Science report to Bolt January 2025. Includes first, second, and third line therapy for US, UK, France, Germany, Italy, Spain, Japan and China.

BOLT BIOTHERAPEUTICS

BDC-4182 Has the Potential to Double Current Claudin 18.2 Market

BDC-4182 has the potential to expand the market AND to outperform other claudin 18.2-directed therapies in tumors with lower antigen expression



Vyloy® (zolbetuximab) is approved for use in tumors with ≥75% IHC2+, ~40% of the market

Preclinical data published in Fu CL et al. SITC 2025

BDC-4182 Preclinical Data

BDC-4182 First-in-Class ISAC

Solid preclinical foundation supported by 10+ years of innovation and learnings

BDC-4182



Next-Generation Claudin 18.2 ISAC

Powerful on-target immune activation

- Immune activation correlates with antigen density in tumor-bearing mice
- Limited activity in tumor-naïve mice and non-human primates

Eradicates tumors across the antigen spectrum

- Complete regression seen in multiple ultra-low antigen density models
- Myeloid killing of antigen-positive tumors initiates broad immune response

Epitope spreading enables the killing of antigen-negative tumors

- Protection from rechallenge with antigen-negative tumors
- Immunological memory and protection is dependent on T cells

Outperforms ADCs at ultra-low antigen density

- Superior anti-tumor activity relative to MMAE and TOPO1-based ADCs
- Beats AZD0901 at multiple dose levels in ultra-low syngeneic model

BOLT BIOTHERAPEUTICS

Immune Activation in the Periphery is on Target and Tumor-Dependent

Limited activity observed with BDC-4182.S in tumor-naïve mice



C57BL/6 mice bearing KPC-mCLDN18.2 tumors were treated via IP injection with the indicated test articles at 1 mg/kg. Plasma cytokines and chemokines were measured 4 hours after dosing (n=4 per group).

BDC-4182 Targets Ultra-low Claudin 18.2 Tumors

BDC-4182.S eradicates low-antigen tumors in preclinical xenograft models

NUGC4-hCLDN18.2 (IHC 2+ ≥ 25%)



NCI-N87-hCLDN18.2 (IHC 2+ ≥ 1%)



PA-TU-8988S (IHC 2+ ≥ 1%)



Claudin 18.2 mAb Control | Isotype mAb Control | BDC-4182.S | Isotype ISAC Control

Compelling Activity Despite the Lack of Functional B, T or NK cells

Adapted from Fu CL et al., SITC 2024.
SCID/beige mice bearing the indicated tumors were treated with BDC-4182.S (BDC-4182 surrogate) at 5 mg/kg BIW (4 total doses, n=8 per group). NUGC4 and NCI-N87 are gastric cancer cell lines, engineered here to express claudin 18.2. PA-TU-8988S is a pancreatic cancer cell line that endogenously expresses claudin 18.2.

BOLT BIOTHERAPEUTICS

BDC-4182 Has Curative Potential

BDC-4182.S induces immunological memory & epitope spreading; T cells kill tumors that lack CLDN18.2

Eliminates Ultra-low Antigen-positive Tumors

MC38-CLDN18.2 (IHC 2+ ≥ 1%)



Rechallenge with MC38 cells lacking CLDN18.2

± T cell depletion

Expands to Antigen-negative Tumors

Parental MC38 line (no CLDN18.2)



Adapted from Fu CL et al. SITC 2025

BDC-4182.S treated mice (5 mg/kg, q5dx3) with complete tumor regression for > 28 days following their last treatment were rechallenged with MC38-mCLDN18.2 cells (IHC1+ by H-score) on their right flank and parental MC38 cells on the left flank in the presence of absence of CD4 & CD8 T cell depletion (n=4 mice/group).

BDC-4182 Has Potential for Superior Anti-tumor Activity versus ADCs

BDC-4182.S outperforms cytotoxic ADCs in syngeneic model at ultra-low antigen density

Superior to MMAE ADC

Limited ADC Efficacy in MC38 **Ultra-low Model** (IHC 2+ ≥ 1%)



Superior to TOPO1 (DXd) ADC

Limited ADC Efficacy in MC38 **Ultra-low Model** (IHC 2+ ≥ 1%)



Adapted from Fu CL et al., SITC 2024
C57BL/6 mice bearing MC38-mCLDN18.2 tumors (IHC 1+ by H-score) were administered 5 mg/kg of the indicated test article biweekly for 4 doses (dashed lines; n=6 to 8 mice/group)

BOLT BIOTHERAPEUTICS

Summary

Next-generation ISACs are Dramatically Better than First-generation ISACs

Across multiple tumor antigens with varying expression levels

HER2
HCC1954 Model >500K Molecules/Cell



HER2
JIMT-1 Model ~25K Molecules/Cell



TROP2
JIMT-1 Model ~50K Molecules/Cell



CEA
HPAF-II Model ≥60K Molecules/Cell

Not Shown: 17.4% TGI for First-Gen ISAC in separate study



Naked mAb Control **First-generation ISAC** **Next-generation ISAC** **Isotype mAb**

Adapted from Ptacek J et al. SITC 2024
Mice bearing tumors with the indicated cell line were treated with 5 mg/kg or 2.5 mg/kg Q5D x 4 of the indicated tumor-targeting naked mAb, tumor-targeting ISAC or isotype mAb.

BOLT BIOTHERAPEUTICS

Harnessing the Immune System to Improve Lives and Eradicate Cancer

BDC-4182 will provide proof-of-principal for the ISAC approach

BDC-4182 (claudin 18.2 ISAC) Phase 1/2 clinical trial ongoing

- First-in-class, best-in-class Immune Stimulating Antibody Conjugate (ISAC)
- Initial clinical data from >10 patients will be presented with 3Q26 results



ISAC proof-of-concept should have a substantial multiplier effect

- ISACs have potential to combine the power of ADCs with the durability of T cell engagers
- Industry is hungry for ADC payloads beyond Topo1 to overcome resistance issues
- Pipeline of Boltbody™ ISACs (CEA, PD-L1, Genmab & Toray collaboration programs)

Operating runway into 1Q27[1]

- BDC-4182 initial clinical data expected to be a key inflection point

[1] Cash, cash equivalents, and marketable securities balance of $18.1 million as of 6/30/2026

BOLT BIOTHERAPEUTICS

Thank you